Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Netupitant/palonosetron (Akynzeo -- Purdue Pharma) indication : chemotherapy-induced nausea and vomiting

The CADTH Canadian Drug Expert Committee (CDEC) recommends that netupitant/palonosetron, in combination with dexamethasone, be reimbursed for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC)...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, June 20, 2018
Edition:Final
Series:CADTH common drug review
Subjects:
Canada
Nausea / Drug Therapy
Cost-benefit Analysis
Antiemetics / Therapeutic Use
Insurance, Pharmaceutical Services / Economics
Insurance, Health, Reimbursement / Economics
Drug Costs
Drug-related Side Effects And Adverse Reactions / Drug Therapy
Antiemetics / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that netupitant/palonosetron, in combination with dexamethasone, be reimbursed for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC), if the following criterion and condition are met: reimburse in a manner similar to aprepitant within drug plans that already reimburse aprepitant for the prevention of nausea and vomiting associated with HEC.
Physical Description:1 PDF file (7 pages)

Similar Items